蛇蝎美人第二季

mRNA癌症疫苗不是梦？_我的网站

A |     BioNTech是德国一家生物技术公司，主要业务为开发和生产针对特定患者的治疗严重疾病的有效免疫疗法。    The Build Back Better World (B3W) program was pompously announced by the club of seven developed nations to counter China's Belt and Road at the G7 Summit in Cornwall in July 2021. However, little had been heard of the G7's endeavor since then. In June 2022, the Group of Seven decided to breathe new life into the project.,"So far, America has failed to build momentum on its plan to Build Back a Better World," says Francesco Sisci, a Beijing-based China expert, author, and columnist. "However, with this new G7 plan, which includes other countries, this momentum could start to be built. It is a question mark. Nobody is sure until things are realized. But you cannot just underestimate and dismiss this plan, because there is a large commitment of many countries with a large economy and this plan could make big sense.",The G7's grand design envisages laying a secure sub-sea telecommunications cable that will connect Singapore to France through Egypt and the Horn of Africa; creating a COVID-19 vaccine plant in Senegal; expanding solar projects in Angola, including solar mini-grids and home power grids; and establishing an innovative modular nuclear reactor plant in Romania, among other issues.,The US president pledged to mobilize $200 billion in investments in global infrastructure projects over the next five years. The overall investment, including G7 member states and private capital, is expected to reach $600 billion.,"With two competing plans - size matters, at the end of the day," says Sisci. "That is, China may be able to immediately finalize a lot of money in a short time in a number of projects. The G7 countries could be slower, but eventually they could build up momentum and they could channel much more money much more effectively, perhaps, in a much larger number of projects which could stifle Chinese projects.",Sisci suggests that the club of developed capitalist countries "may end up being more effective in many ways [than China], a smaller non-capitalist country.","China, but also Russia, by far, don't have the size, the gravitas to oppose even a divided G7, which is coming together because of this opposition to China or Russia-driven projects," he notes.,UK's Looming Recession is Self-Inflicted, BoJo and BoE are to Blame, Economists Say19 June, 12:09 GMT,G7 Economic & Geopolitical Hurdles,However, some other observers express skepticism over the ability of the US and G7 to implement the project given record-high inflation and cost of living crisis currently engulfing the states. The US, British and European central banks are struggling to tame skyrocketing inflation by raising interest rates to reduce demand, which is prompting recession fears.,"Washington claims they are going to be sending over $200 billion. But where's the money coming from and how is it going to be really used?" asks Thomas W. Pauken II, the author of "US vs China: From Trade War to Reciprocal Deal," a consultant on Asia-Pacific affairs and a geopolitical commentator.,He notes that previously the US Senate voted Biden's landmark Build Back Better initiative down, and for good reason, as Republican congressmen feared that the Democratic administration's spending spree would fan inflation and increase an already bloated national debt.,Pauken also expresses bewilderment over the G7's apparent readiness to embark on the bold international project at a time when the group is involved in the Ukraine crisis with the UK trying to keep the military conflict dragging on. "I mean, it's laughable that they have to think about [competing with] China at this time when they're on the brink of a major war in Europe," the commentator remarks.,Challenge or Opportunity? How China's Digital Silk Road May Change Global Technology Order16 April 2021, 04:00 GMT,Meanwhile, the G7's Global Investment and Infrastructure Partnership cannot be regarded so far as a viable alternative to the Beijing-led Belt and Road Initiative that has been implemented for slightly less than a decade, according to Pauken.,"First of all, [the G7] actually need[s] to make these projects work," says the geopolitical commentator. "Other than that solar plant in Angola, I don't see any of these initiatives really working.",In particular, China invested almost $59.5 billion in its comprehensive infrastructure project in 2021 alone. When it comes to crucial elements of the project, the West appears to be lagging behind. While the G7 is still considering building a subsea cable linking Europe and Southeast Asia, China kicked off its Digital Silk Road (DSR) almost seven years ago. The DSR's backbone is the Pakistan and East Africa Connecting Europe (PEACE), a 9,300 mile long subsea cable network meant to tie Asia, Africa, and Europe together. The network is designed to transmit over 16Tbps per fibre pair with its Mediterranean section going from Egypt to France having already been laid.,WFP Announces Cuts in Food Rations for Refugees in East, West Africa Due to Lack of Funds20 June, 17:13 GMT,Are Emerging Economies Interested in the G7 Agenda?,There is yet another problem as to how to make these Western projects attractive for Global South nations, the Asia Pacific expert continues. In particular, the G7 has been pushing ahead with a climate change agenda and the plan to cut carbon emissions, which is not relevant for the majority of third-world states which are still reliant on cheaper and more reliable fossil fuels and coal plants, he notes.,"You also have to deal with auditing issues as well as the so-called climate change consultants who go on the ground and on site," he says. "You have to prove that those infrastructure projects are not causing much of a carbon footprint. But most of the major infrastructure does require a big carbon footprint, especially in the emerging markets, because they don't have the same equipment or they don't have the same standards or labor laws as they would have in Western Europe or the US.",Many emerging economies, including African countries, are beginning to have a growing frustration with the US and Europe, according to Pauken. The reality is that Africans and many of the emerging markets want to focus on economic stuff, he notes. However, when the US officials come in, they're talking about climate change or gender equity, and this is not as interesting to developing nations, the commentator emphasizes.,"[Developing nations] want help on improving their agricultural production levels and boosting their energy capacity, which the Russians and the Chinese have been doing," Pauken notes.,Given all of the above, it is unlikely that the G7's Global Investment and Infrastructure Partnership initiative is going to actually happen, argues the geopolitical commentator.,"They're rebranding a failed policy, thinking it might work by using new names and new mergers. Last time it was separate between the EU and separate between the US and they somehow think that if you combine the two failed projects into one, that this will somehow succeed. That's not going to work in the real world," Pauken concludes.。

B | 在新冠疫情暴发之前，BioNTech一直在研究mRNA癌症疫苗。但在疫情全球蔓延之后，该公司转而研发新冠疫苗。在新冠疫情期间，辉瑞公司与百欧恩泰公司联合开发的mRNA疫苗是美国食品和药物管理部门批准的第一个新冠肺炎疫苗。

C | 当时，该疫苗显示出了91%的有效性，此后被证明能够减少因新冠肺炎导致的住院和死亡人数。

D | 此外，Moderna的mRNA新冠疫苗也经美国药品监督管理局FDA批准获得紧急使用授权，直接推动mRNA疫苗成为全球关注热点，2021年度《麻省理工科技评论》“全球十大突破性技术”名单之首即为mRNA疫苗。在那之后，诸多药企入局，希望将mRNA疫苗的适应证范围扩展到其他感染性疾病、肿瘤等领域。科学家们称，这场大流行病可能造成的影响之一就是加速癌症疫苗的发明。据BioNTech官网，该公司现在有几种癌症疫苗处于临床试验阶段。

E | 其拥有超过30个产品管线，肿瘤相关的约15个，其正在开发针对直肠癌、黑色素瘤和其他癌症类型的治疗方法。吴沙忻表示，辉瑞和BioNTech成功研发出新冠疫苗，也推动了该公司在研发癌症疫苗方面的工作。有业内人士表示，在大的分类上，肿瘤疫苗可区分为预防性肿瘤疫苗和治疗性肿瘤疫苗。其中，最为典型和广为人熟知的预防性肿瘤疫苗即为HPV疫苗，预防宫颈癌发生。但作为治疗疫苗，mRNA癌症疫苗研发难度仍然较大。疫苗专家陶黎纳表示，与通过较弱版本病毒制造出的传统疫苗不同，mRNA技术只使用病毒的遗传密码。当mRNA进入人体时，它也会进入细胞，令其制造相关抗原。

F | 因此，mRNA疫苗在疫苗作用机制上并无突破，就是刺激免疫系统的强度大了不少，是否能成就癌症疫苗的招牌，有待实践检验。此外，因为构成肿瘤的癌细胞中可能含有多种不同的蛋白质，使得制造针对所有癌细胞而不针对健康组织的疫苗变得极其困难。“疫苗的免疫机制是利用免疫系统针对异己的免疫反应。免疫系统也有针对叛变的自己——癌细胞的免疫机制，但和针对异己的不一样。所以，以建立在针对异己机制上的疫苗原理，去研发针对自己细胞的癌症疫苗，存在机制上的限制，难度大在这里。” 陶黎纳进一步解释道。对于疫苗上市的时间以及是否有效等问题，北京商报记者联系了BioNTech方面，但截至发稿还未收到回复。不过BioNTech对此持谨慎态度。

G | 蒂雷吉表示，作为科学家，不能轻言“治愈”癌症，但目前已经取得了许多突破。事实上，此前已有企业在布局癌症疫苗。2010年4月，FDA批准第一款治疗性疫苗Provenge，用于治疗前列腺癌。但Provenge并未带来颠覆性的疗效。临床试验结果显示，比起对照组，Provenge仅将患者的总体生存期延长4.1个月。

H | 但Provenge的销量未达预期，其研发公司Dendreon也以破产告终。

I | 因为Provenge疗效一般，但价格昂贵。Provenge属于自体细胞免疫疗法，需使用患者自身的免疫细胞制造，成本较高，每疗程价格高达9.3万美元。而同样治疗前列腺癌的阿比特龙和恩杂鲁胺分别在2011年和2012年上市，价格仅为Provenge的一半。

J | 值得注意的是，除了BioNTech，在mRNA药物治疗领域，Moderna、默沙东、葛兰素史克、斯微生物、艾博生物等企业均有布局。截至2022年3月31日，全球mRNA药物进入临床管线的共有56个，研发主要集中在疫苗领域。智慧芽全球新药情报库Pharmsnap数据平台显示，BioNTech和Moderna是走在前沿的两家企业，结直肠癌、黑色素瘤等在研适应症均处于临床2期。据报道，10月中旬，Moderna宣布与国际药企默沙东合作，将联合开发并销售一种个性化精准治疗癌症疫苗，推动Moderna的mRNA技术与默沙东PD-1肿瘤疗法Keytruda（K药）联用，探索治疗高危黑色素瘤患者。根据协议，默沙东将向Moderna支付2.5亿美元。

Current article:http://q5zz.tibiantasangnenti.buzz/list_hj3/rxzf.html

Published on:08:15:12